Twist Bioscience (NASDAQ:TWST) Stock: Insider Emily Leproust Sells 4,573 Shares

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 4,573 shares of the company’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total transaction of $619,184.20. Following the completion of the transaction, the chief executive officer owned 558,187 shares of the company’s stock, valued at $75,578,519.80. This trade represents a 0.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Twist Bioscience Stock Down 15.5%

Twist Bioscience stock traded down $22.05 during trading hours on Thursday, hitting $120.53. 3,054,516 shares of the stock traded hands, compared to its average volume of 1,763,809. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $219.71. The company has a market cap of $7.56 billion, a PE ratio of -54.29 and a beta of 2.25. The firm’s 50-day moving average price is $152.59 and its two-hundred day moving average price is $90.28.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The firm had revenue of $118.38 million during the quarter, compared to the consensus estimate of $114.55 million. During the same quarter last year, the company posted $0.33 EPS. Twist Bioscience’s revenue for the quarter was up 23.2% compared to the same quarter last year. On average, research analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Analysts Set New Price Targets

Several analysts have commented on the company. Piper Sandler increased their target price on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. UBS Group assumed coverage on shares of Twist Bioscience in a research report on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price objective on the stock. TD Cowen raised their target price on shares of Twist Bioscience from $115.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Jefferies Financial Group began coverage on shares of Twist Bioscience in a research report on Thursday, October 8th. They issued a “hold” rating and a $150.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a report on Monday, September 21st. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $153.00.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Root Financial Partners LLC bought a new stake in shares of Twist Bioscience during the 3rd quarter valued at $33,000. Signaturefd LLC raised its holdings in Twist Bioscience by 94.3% in the 3rd quarter. Signaturefd LLC now owns 548 shares of the company’s stock worth $106,000 after purchasing an additional 266 shares during the period. Allworth Financial LP purchased a new position in Twist Bioscience during the second quarter valued at $62,000. Trifecta Capital Advisors LLC bought a new stake in Twist Bioscience during the second quarter valued at about $63,000. Finally, Western Wealth Management LLC purchased a new stake in Twist Bioscience in the first quarter worth about $31,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.